About: Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2011 (uk) im Juni 2011 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58448092-4173A322-A003-40A2-993C-7E21B26E9AA0
publication date	2011-03-30 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58448092-499D49DA-C40B-4CDA-989E-EFFE44B326AB
language of work or name	English
author name string	wds:Q58448092-0BA07C84-87ED-47D6-A0EF-1F3730F5BCAF wds:Q58448092-2BDF4820-DFC2-4B7C-B6D2-7420C9248828 wds:Q58448092-B0A450EE-D3A9-4DA6-88A3-86ACE09B37AB wds:Q58448092-DCBF087D-5890-4A24-AC06-44FF4690C577 wds:Q58448092-FBAC209A-7710-43B9-9C37-4CE6F064D8F5
author name string	Michael Nauck Wolfgang E Schmidt Alan Garber Jason H Brett Nicoline Videbæk
rdfs:label	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria (en) Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (nl)
skos:prefLabel	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria (en) Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (nl)
name	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria (en) Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (nl)
author	wds:Q58448092-894789FB-2D23-4D92-B7AF-48992BA1DD9A wds:Q58448092-F884A23B-239D-4866-ADDF-0DE0633CC7EC wds:Q58448092-FDEEE4E6-EE84-4D61-9435-26631CA2232E
author	John Buse Jens Juul Holst Julio Rosenstock
title	wds:Q58448092-162D96AE-13CF-48BF-A08A-7AF9180B7B09
title	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials (en)
page(s)	wds:Q58448092-34EF4CA8-AF06-4BFE-BA32-0758AF4C86C9
page(s)	1695-1702
instance of	wds:Q58448092-C324E06D-B3D9-4D78-8F58-E577DD2978FD
instance of	scholarly article
main subject	wds:Q58448092-54377DBA-355C-4FFB-A411-E6D2B3899305 wds:Q58448092-EF6C60CF-3AF1-48A2-819F-4DF41ECF6695
main subject	antibody liraglutide
PubMed ID	wds:Q58448092-6A953551-688C-4E59-906E-D8929460A091
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21450987
PubMed ID	21450987
published in	wds:Q58448092-D5634BDF-EF36-4021-B520-05156522AA76
published in	The Journal of Clinical Endocrinology and Metabolism
issue	wds:Q58448092-14BBFE87-C15E-4685-BA7A-05A461A54B80
volume	wds:Q58448092-9B803FA5-9860-413A-AA06-277858FD44E2
issue	6
volume	96
DOI	wds:Q58448092-468B8AC7-D00F-4ECB-8BF2-1A32898DA8C3
DOI	http://dx.doi.org/10.1210/JC.2010-2822
DOI	10.1210/JC.2010-2822
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58448092
is cites work of	Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials Update on incretin hormones Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Comparative effectiveness of liraglutide in the treatment of type 2 diabetes Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus Gut hormones: the future of obesity treatment? GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists Liraglutide for Type 2 diabetes and obesity: a 2015 update Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum Incretin therapy--present and future Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes Recent advances in incretin-based therapies Liraglutide-induced autoimmune hepatitis Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance Next-generation GLP-1 therapy: an introduction to liraglutide Site-specific fatty acid-conjugation to prolong protein half-life in vivo An overview of new GLP-1 receptor agonists for type 2 diabetes Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus Glucagon-like peptide 1 in health and disease Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics A Plethora of GLP-1 Agonists: Decisions About What to Use and When Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc Exenatide: pharmacokinetics, clinical use, and future directions Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Emerging role of insulin with incretin therapies for management of type 2 diabetes Biosimilar insulins: guidance for data interpretation by clinicians and users Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors Adverse Effects of GLP-1 Receptor Agonists Comparing diabetes drugs--helping clinical decisions? Liraglutide in oral antidiabetic drug combination therapy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software